Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.

Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC

Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

A childhood dream became a reality for Montana native Kelly K. Hunt, MD, FACS, FSSO, who has changed the face of the surgical breast oncology workforce.

One Surgeon’s Spirit and Brilliance Lift a Whole Community

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

A national data analysis published by researchers from Penn Medicine reported that short-term mortality was not impacted for patients with advanced cancers during the shortage of generic platinum chemotherapy drugs.


Generic Platinum Chemotherapy Shortages Did Not Increase Deaths

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

1rem

primary

View

Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC)  

An Overview of the Molecular Characterization of Lung LCNEC

What are some of the challenges with differential diagnosis?

Videos

Panelists discuss how the management of lung large cell neuroendocrine carcinoma (LCNEC) involves a multidisciplinary approach, focusing on molecular characterization, biomarker testing, and emerging treatment options, including novel targeted therapies and ongoing clinical trials.

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is characterized by its biology, incidence, risk factors, clinical presentation, and prognosis, while addressing the challenges, unmet needs, and the trial data required to guide testing and treatment guidelines for this rare cancer.

Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

Panelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is diagnosed, including the challenges associated with its differential diagnosis.

The Pathological Diagnosis of Lung LCNEC 

Panelists discuss how biomarker testing for lung large cell neuroendocrine carcinoma (LCNEC) is approached, covering the frequency and types of tests used, such as NGS, the timing of DLL3 testing, and the factors influencing the choice between fine needle aspirate and other biopsy techniques.

Biomarker Testing Strategies for Lung LCNEC 

Panelists discuss the factors that influence the decision to perform a fine needle aspirate vs an incisional biopsy, whether testing is conducted in-house or at a central laboratory, and how the results of these tests impact the treatment plan for patients with lung large cell neuroendocrine carcinoma (LCNEC).

Biopsy Best Practices: Diagnosing Lung LCNEC

Panelists discuss the challenges encountered with molecular or pathology testing for lung large cell neuroendocrine carcinoma (LCNEC) and how treatment plans are determined when testing is not feasible.

Lung LCNEC Diagnostic Challenges

Panelists discuss the vital multidisciplinary coordination needed to optimize care for patients with lung large cell neuroendocrine carcinoma (LCNEC), including the roles of various specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the importance of involving the patient in these discussions.

A Multidisciplinary Approach to Managing Lung LCNEC

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Lung LCNEC Disease Histology and Prognosis

The Role of DLL3 in LCNEC of the Lung

Panelists discuss their impressions of the LANCE pilot study for atezolizumab in lung large cell neuroendocrine carcinoma (LCNEC) and its potential impact on treatment strategies.

Insights on the LANCE Pilot Study on Lung LCNEC

Panelists discuss how novel targeted therapies, such as T-cell engagers, could improve outcomes for patients with lung large cell neuroendocrine carcinoma (LCNEC) and other neuroendocrine cancers (NECs).

Novel Targeted Therapies for LCNEC of the Lung

Panelists discuss ongoing trials with BI 764532 and their potential impact on the treatment of lung large cell neuroendocrine carcinoma (LCNEC).

The Pathological Diagnosis of Lung LCNEC

EP: 1.Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

EP: 2.An Overview of the Molecular Characterization of Lung LCNEC

EP: 3.The Pathological Diagnosis of Lung LCNEC

EP: 4.Biomarker Testing Strategies for Lung LCNEC

EP: 5.Biopsy Best Practices: Diagnosing Lung LCNEC

EP: 6.Lung LCNEC Diagnostic Challenges

EP: 7.A Multidisciplinary Approach to Managing Lung LCNEC

EP: 8.Lung LCNEC Disease Histology and Prognosis

EP: 9.The Role of DLL3 in LCNEC of the Lung

EP: 10.Insights on the LANCE Pilot Study on Lung LCNEC

EP: 11.Novel Targeted Therapies for LCNEC of the Lung

EP: 12.Overview of Studies of BI 764532 for Lung LCNEC

Latest Conference Coverage